Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
07 Oct 2021 | Liquidity and counterparty agreements | Download | |
04 Oct 2021 | Liquidity and counterparty agreements | Download | |
01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
28 Jul 2021 | On business and financial situation | ROVI releases the first half 2021 results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
24 Feb 2016 | Informe anual de remuneraciones de los consejeros 2015 | ROVI releases the 2015 annual report regarding remuneration of the members of the Board of Directors | Download |
23 Dec 2015 | Otros sobre operaciones corporativas | Download | |
21 Dec 2015 | Otros sobre operaciones corporativas | Download | |
01 Dec 2015 | Otros sobre gobierno corporativo | Download | |
01 Dec 2015 | Otros sobre Gobierno Corporativo (2) | Download |